Somatostatin analog and pegvisomant combination therapy for acromegaly

Keyphrases

• Combination Therapy 100%
• Somatostatin Analogs 100%
• Pegvisomant 100%
• Combination Treatment 75%
• Monotherapy 50%
• Quality of Life 50%
• Clinically Significant 25%
• Growth Factors 25%
• Insulin-like 25%
• Tumor Size 25%
• Adverse Effects 25%
• Type 1 Diabetes Mellitus (T1DM) 25%
• Long-term Efficacy 25%
• Pituitary Tumor 25%
• Increased Mortality 25%
• Highly Effective 25%
• Long-acting Somatostatin Analogues 25%
• Biochemical Control 25%
• Growth Hormone Receptor Antagonist 25%
• Disease Symptoms 25%
• Transaminases 25%
• Long-term Safety 25%
• Tumor Combination Therapy 25%
• Low-level Control 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Acromegaly 100%
• Somatostatin Derivative 100%
• Pegvisomant 100%
• Monotherapy 40%
• Neoplasm 20%
• Disease 20%
• Adverse Event 20%
• Diabetes Mellitus 20%
• Hypophysis Tumor 20%
• Somatomedin C 20%
• Aminotransferase 20%
• Physical Disease by Body Function 20%
• Growth Hormone Receptor 20%
• Hormone Receptor Blocking Agent 20%

Neuroscience

• Pegvisomant 100%
• Acromegaly 100%
• Somatostatin Derivative 100%
• Diabetes Mellitus 20%
• Adverse Effect 20%
• Pituitary Tumour 20%
• Insulin-Like Growth Factor 1 20%
• Receptor Antagonist 20%
• Transaminase 20%
• Growth Hormone Receptor 20%